Pulmonary MCP-1 expression after prenatal treatment with rosiglitazone.
- Jan-Hendrik Gosemann (325605)
- Florian Friedmacher (5954441)
- Alejandro Hofmann (5954444)
- Julia Zimmer (325882)
- Joachim F. Kuebler (325607)
- Susanne Rittinghausen (129639)
- Anne Suttkus (709106)
- Martin Lacher (3913042)
- Luis Alvarez (233360)
- Nicolae Corcionivoschi (463527)
- Prem Puri (195256)
Publication date
November 2018
DOI Publisher
Public Library of Science (PLoS)Abstract
After prenatal treatment with rosiglitazone (CDH+R; E, F), no increase in thickness of pulmonary vessels as well as of MCP-1 and SMA immunoreactivity could be observed in CDH lungs compared to controls (control; A, B). Treatment with placebo only resulted in the typical medial and adventitial changes as well as increased immunoreactivity of MCP-1 and SMA in the pulmonary vasculature of CDH fetuses (CDH+P; C, D). Scale bar 30 μm.</p
Add to ORKG